培高利特对帕金森病患者的长期疗效。

Long-term efficacy of pergolide in patients with Parkinson's disease.

作者信息

Sage J I, Duvoisin R C

出版信息

Clin Neuropharmacol. 1986;9(2):160-4. doi: 10.1097/00002826-198604000-00007.

DOI:10.1097/00002826-198604000-00007

Abstract

We report the clinical course of 35 patients with Parkinson's disease who experienced an initially favorable response to pergolide and who were taking the drug for at least 6 months. The duration of pergolide treatment was 6-50 (25 +/- 16 SD) months. Of the 14 patients who remained on pergolide for over 2 years, 12 remained less disabled for 26 +/- 17 SD months, seven enjoyed increased "on" time for 39 +/- 8 SD months, and nine had a lower Hoehn-Yahr stage for 25 +/- 17 SD months. Pergolide was discontinued after 5-39 months in eight patients; six patients then deteriorated. Pergolide can remain efficacious in the treatment of Parkinson's disease for up to 50 months.

摘要

我们报告了35例帕金森病患者的临床病程，这些患者最初对培高利特反应良好且服用该药至少6个月。培高利特治疗时长为6 - 50（25±16标准差）个月。14例服用培高利特超过2年的患者中，12例在26±17标准差个月内残疾程度减轻，7例“开”期增加39±8标准差个月，9例Hoehn - Yahr分期降低25±17标准差个月。8例患者在5 - 39个月后停用培高利特；其中6例随后病情恶化。培高利特在治疗帕金森病中可持续有效长达50个月。